KalVista Pharmaceuticals ... (KALV)
10.85
-0.54 (-4.78%)
At close: Mar 03, 2025, 3:59 PM
10.87
0.18%
After-hours: Mar 03, 2025, 04:00 PM EST
KalVista Pharmaceuticals Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Cash & Equivalents | 31.79M | 56.24M | 30.73M | 50.59M | 15.79M | 32.01M | 51.05M | 30.95M | 21.76M | 3.9M | 9.78M | 8.24M |
| Short-Term Investments | 178.61M | 93.14M | 135.47M | 198.34M | 51.92M | 68.81M | n/a | n/a | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 199K | n/a | n/a | n/a |
| Other Long-Term Assets | 567K | 106K | 193K | 200K | 178K | 173K | 173K | n/a | -199K | 1.88M | 120K | 120K |
| Receivables | 10.87M | 16.57M | n/a | 10.42M | 16.53M | 11.31M | 6.83M | 2.55M | 356K | n/a | n/a | n/a |
| Inventory | n/a | n/a | 2.71M | n/a | n/a | n/a | n/a | n/a | n/a | -235.41 | n/a | n/a |
| Other Current Assets | 4.42M | 4.31M | 10.64M | 3.62M | 4.46M | 3.42M | 1.49M | 701K | 668K | 217.81K | 129K | 83K |
| Total Current Assets | 225.69M | 172.33M | 193.65M | 264.26M | 88.7M | 115.55M | 59.38M | 34.25M | 24.67M | 4.59M | 9.91M | 8.32M |
| Property-Plant & Equipment | 9.15M | 10.77M | 10.04M | 7.55M | 3.65M | 2.41M | 1.84M | 97K | 74K | 180K | 75K | 84K |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 9.71M | 10.88M | 10.23M | 7.75M | 3.83M | 2.59M | 2.01M | 97K | 74K | 2.06M | 195K | 204K |
| Total Assets | 235.4M | 183.2M | 203.88M | 272.01M | 92.53M | 118.13M | 61.39M | 34.34M | 24.75M | 6.64M | 10.11M | 8.53M |
| Account Payables | 9.11M | 4.82M | 3.64M | 1.98M | 1.68M | 2.86M | 1.43M | 1.15M | 1.01M | 1.02M | 462K | 147K |
| Deferred Revenue | n/a | n/a | n/a | n/a | n/a | 9.54M | 18.48M | n/a | 29K | 29K | 29K | 23K |
| Short-Term Debt | 1.3M | 1.09M | 977K | 863K | 588K | 54K | 221K | n/a | n/a | 4.43M | 3.06M | 2.69M |
| Other Current Liabilities | 12.4M | 9.13M | 6.96M | 6.93M | 5.46M | 5.59M | 3.09M | 1.86M | 2.21M | 1.6M | 396K | 213K |
| Total Current Liabilities | 22.81M | 15.03M | 11.58M | 9.77M | 7.72M | 18.05M | 23.22M | 3.02M | 3.25M | 7.09M | 3.95M | 3.07M |
| Long-Term Debt | 6.01M | 7.14M | 7.21M | 5.05M | 1.06M | n/a | 58K | n/a | n/a | 2.13M | n/a | n/a |
| Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -56K | 38.24M | 39.75M | 33.63M |
| Total Long-Term Liabilities | 6.01M | 7.14M | 7.21M | 5.05M | 1.06M | 3.34M | 10.92M | 1.15M | 1.01M | 43.73M | 39.86M | 33.75M |
| Total Liabilities | 28.82M | 22.18M | 18.79M | 14.82M | 8.78M | 21.39M | 34.14M | 3.02M | 3.25M | 50.83M | 43.81M | 36.81M |
| Total Debt | 7.32M | 8.23M | 8.19M | 5.91M | 1.65M | 54K | 279K | n/a | 4.61M | 6.57M | 3.06M | 2.69M |
| Common Stock | 42K | 34K | 25K | 24K | 18K | 17K | 11K | 10K | 3K | 1K | 2K | 2K |
| Retained Earnings | -469.73M | -343.08M | -250.18M | -167.84M | -121.59M | -92.48M | -71.66M | -55.85M | -37.25M | -47.77M | -34.42M | -28.74M |
| Comprehensive Income | -3.49M | -3.06M | -3.86M | -1.43M | -1.88M | -1.93M | -1.11M | -2.64M | -75K | -495K | -441K | -414K |
| Shareholders Equity | 206.58M | 161.03M | 185.09M | 257.19M | 83.75M | 96.74M | 27.25M | 31.33M | 21.5M | -44.18M | -33.71M | -28.29M |
| Total Investments | 178.61M | 93.14M | 135.47M | 198.34M | 51.92M | 68.81M | n/a | n/a | 199K | n/a | n/a | n/a |